Keytruda, Merck
Neoadjuvant Pembrolizumab Modifies Tumor Burden Effect in Triple-Negative Breast Cancer
Neoadjuvant pembrolizumab (Keytruda, Merck) was licensed for use in patients with previously untreated ...
JULY 11, 2022
Pembrolizumab Newly Indicated to Treat Advanced Endometrial Carcinoma
The FDA approved pembrolizumab (Keytruda, Merck) for the treatment of patients with microsatellite instability?high ...
MARCH 23, 2022
Keytruda Gains Approval for Treatment of SCLC
The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment of patients who have ...
JUNE 20, 2019
FDA Approves Keytruda for Metastatic Head & Neck Cancers
The FDA approved pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with metastatic or ...
JUNE 11, 2019
Keytruda Gains 2 New First-Line Indications: NSCLC and RCC
The FDA approved pembrolizumab (Keytruda, Merck) for the first-line treatment of patients with stage III/IV ...
APRIL 24, 2019
Keytruda Approved for Adjuvant Rx in Melanoma Patients With Lymph Node Involvement
The FDA approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with melanoma with ...
FEBRUARY 22, 2019
Keytruda Approved for Any Solid Tumor With Specific Biomarker
Granted approval for the treatment of adult and pediatric patients with unresectable or metastatic solid ...
MAY 26, 2017
Keytruda Approved for Urothelial Cancer
The drug was granted approval for the treatment of patients with locally advanced or metastatic urothelial ...
MAY 18, 2017
Keytruda Approved as First-Line Combination Therapy for Metastatic Nonsquamous NSCLC
Approved in combination with pemetrexed and carboplatin for the first-line treatment of metastatic nonsquamous ...
MAY 15, 2017